Table 1 Correlations between circHIPK3 expression and clinical characteristics in CRC patients (n = 178)
From: RETRACTED ARTICLE: CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7
Clinicopathologic parameters | Total (n = 178) | CircHIPK3 expressiona | p value | |
|---|---|---|---|---|
Low (%) | High (%) | |||
Age (years) | ||||
≤65 | 79 | 41 (51.9%) | 38 (48.1%) | 0.763 |
>65 | 99 | 48 (48.5%) | 51 (51.5%) | |
Gender | ||||
Male | 102 | 49 (48.0%) | 53 (52.0%) | 0.650 |
Female | 76 | 40 (52.6%) | 36 (47.4%) | |
Tumor site | ||||
Colon | 115 | 62 (53.9%) | 53 (46.1%) | 0.210 |
Rectum | 63 | 27 (42.8%) | 36 (57.2%) | |
Tumor size (cm) | ||||
≤5 | 107 | 57 (53.3%) | 50 (46.7%) | 0.358 |
>5 | 71 | 32 (45.1%) | 39 (54.9%) | |
Pathological T category | ||||
T1–T2 | 48 | 31 (64.6%) | 17 (35.4%) | 0.028* |
T3–T4 | 130 | 58 (44.6%) | 72 (55.4%) | |
Lymph node metastasis | ||||
N0 | 102 | 59 (57.8%) | 43 (42.2%) | 0.023* |
N1–2 | 76 | 30 (39.5%) | 46 (60.5%) | |
Distant metastasis | ||||
M0 | 155 | 84 (54.2%) | 71 (45.8%) | 0.006** |
M1 | 23 | 5 (21.7%) | 18 (78.3%) | |
TNM stage | ||||
I–II | 121 | 70 (57.8%) | 51 (42.2%) | 0.004** |
III–IV | 57 | 19 (33.3%) | 38 (66.7%) | |
Differentiation | ||||
Well | 23 | 12 (52.2%) | 11 (47.8%) | 0.695 |
Moderate | 129 | 66 (51.1%) | 63 (48.9%) | |
Poor | 26 | 11 (42.3%) | 15 (57.7%) | |
